Findings

What do systematic reviews say?

7 questions · 7 findings · 3 reviews · Hepato-Biliary

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 5 · 71.4%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

External beam radiotherapy (EBRT) vs chemoembolisation

Serious adverse events · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

External beam radiotherapy for unresectable hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone

Serious adverse events · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

External beam radiotherapy for unresectable hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy

Serious adverse events · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 1.5 [0.66, 3.39]
1 study · 34 participants
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Serious adverse events · primary hepatocellular carcinoma

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 1.12 [0.92, 1.34]
5 studies · 438 participants
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 2.69 [1.34, 5.4]
2 studies · 172 participants
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 1.67 [0.66, 4.27]
4 studies · 280 participants
Very low